PERSEPT 3: A phase 3 clinical trial to evaluate the haemostatic efficacy of eptacog beta (recombinant human FVIIa) in perioperative care in subjects with haemophilia A or B with inhibitors - Escobar -
Haemophilia - Wikipedia
Emicizumab Prophylaxis in Hemophilia A with Inhibitors | NEJM
What is the mechanism of action of emicizumab? - Quora
Frontiers | Bispecific Antibodies: From Research to Clinical Application
Factor Viii Deficiency disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials
Emicizumab: Uses, Interactions, Mechanism of Action | DrugBank Online
Hepatitis C: Most Up-to-Date Encyclopedia, News & Reviews
Arun KEEPANASSERIL | Research and Data Operations Lead, McMaster Hemophilia Resrarch Group | MDS,MSc,CPHIMS -CA | McMaster University, Hamilton | McMaster | Health Information Research Unit (HIRU) | Research profile
Genentech: Hemlibra® (emicizumab-kxwh) - Information for Patients
Simoctocog Alfa (Nuwiq) in Previously Untreated Patients with Severe Haemophilia A: Final Results of the NuProtect Study
Valoctocogene Roxaparvovec and Emicizumab for Hemophilia A without Inhibitors: Effectiveness and Value
Frontiers | Bispecific Antibodies: From Research to Clinical Application
Roche - Wikipedia
Bispecific antibodies are progressing in cancer clinical trials
An anti–glypican 3/CD3 bispecific T cell–redirecting antibody for treatment of solid tumors | Science Translational Medicine
File:Emicizumab.png - Wikimedia Commons
Haemophilia - Wikipedia
Emicizumab: Uses, Interactions, Mechanism of Action | DrugBank Online
Frontiers | Bispecific Antibodies: From Research to Clinical Application
PharmaWiki - Emicizumab
原创】血友病治疗在研项目深度解读系列之Emicizumab（一）：血友病治疗会迎来变革吗？_业界动态_新闻中心_苏州康宁杰瑞生物科技有限公司
Importance of Early Active Engagement of Patients Throughout the Life Cycle of Drug Development
Haemophilia A & B – Blood & Water
